ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Moving Higher On Friday

HC Wainwright & Co. Reiterates Neutral on Biohaven, Maintains $10 Price Target

HC Wainwright & Co. analyst Douglas Tsao reiterates Biohaven (NYSE:BHVN) with a Neutral and maintains $10 price target.

FDA Pauses New Enrollment for Biohaven Epilepsy Drug Program

Biohaven reports an FDA partial clinical hold on BHV-7000 new enrollment while keeping pivotal epilepsy trial data readouts on track.

Biohaven shares are trading lower after the company announced the FDA ordered a pause on new enrollment in BHV-7000 program and issued a partial clinical hold on September 4, pending additional nonclinical metabolite data.

Biohaven Discloses That FDA Demanded Pause In BHV7000-303 Enrolment; Dosing Continues And Topline Data Readout Remains On Timeline For H2 2026

In June 2026, we announced that enrollment in BHV7000-303 was complete. Dosing continues and topline data readout remains on timeline for the second half of 2026. As part of the nonclinical characterization of certain

Under the Radar: 4 Stocks Where Insiders and Management Are Buying

One of the best things about looking for under-the-radar stocks is that you get to spend time in places where Wall Street is not crowding the exits or rushing through the door. You are looking at smaller companies,

8-K filing — BJs RESTAURANTS INC (BJRI)

Filed: 2026-09-09 AccNo: 0001171843-26-005956 Size: 225 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits